Cheaper test to produce, means the reimbursement hopefully will be cheaper. There are certainly enough unhealthy people in the US and having a price which isn't too exorbitant imo will be better for mass adoption. Their competitor's test is over a grand so, if we're much lower obviously the consumers will only have one choice.
Finally, this management team seem to be working for the shareholders, which they have to be commended. It's a long time coming but at least there's some green shoots. Now focus on their other two tests, especially Endo, and then we'll see some real capital growth.
PIQ Price at posting:
36.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)